<DOC>
	<DOCNO>NCT01451580</DOCNO>
	<brief_summary>To determine overall objective response rate pegylated liposomal doxorubicin （Lipo-Dox）combined cyclophosphamide/5-FU second-line treatment patient metastatic breast cancer .</brief_summary>
	<brief_title>Lipo-dox Cyclophosphamide /5-Fluorouracil Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>histologically prove breast cancer metastatic disease life expectancy le 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Phase II</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>